Review: Dual blockade of renin-angiotensin system in diabetic nephropathy: review of literature and local experience

Abstract

Albuminuria and hypertension are predictors of poor renal and cardiovascular outcome in patients with diabetic nephropathy (DN). Intensive treatment requires blockade of the renin-angiotensin system (RAS) by either angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), which reduce blood pressure and proteinuria. Combining the two therapies has shown greater benefits than either drug alone to reduce progression of DN. Although treatment goals are more likely to be achieved with the combination, this requires close monitoring of serum creatinine and potassium which invariably rise on such therapy.

Keywords

diabetic nephropathy dual blockade blood pressure resistant hypertension urine albumin-creatinine blocker creatinine potassium. ratio glomerular filtration rate renin-angiotensin system angiotensin-converting enzyme inhibitor angiotensin receptor blocker potassium.

Get full access to this article

View all access options for this article.

References

Parving HH , Osterby R. , Ritz E. Diabetic Nephropathy. In The Kidney, 6th Edition, Brenner BM , Levine S , Eds Philadelphia, WB Saunders 2000, 1731-73.

Jacobsen P. , Rossing K. , Parving HH Single versus dual blockade of the renin angiotensin system (angiotensin converting enzyme inhibitors and or angiotensin II receptor blockers) in diabetic nephropathy . Curr Opin Nephrol Hypertens 2004;13:319-24.

Rossing P. Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus. Diabet Med 1998 ;15:900-19.

De Jong PE , Navis G. , De Zeeuw D. Renoprotective therapy. Titration against urinary protein excretion. Lancet 1999;354:352-3.

Molitch ME , De Fronzo RA , Franz MJ et al. Diabetic Nephropathy. Diabetes Care 2003;26(suppl):S94-S98.

Thurman JM , Schrier RW Comparative effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am J Med 2003;114:588-98.

Levobitz HE , Weigmann TB , Cnann A. et al. Renal protective effects of enalapril in hypertensive NIDDM- role of baseline albuminuria. Kidney International 1994;145(suppl):S150-S155.

Nielsen FS , Rossing P. , Gall MA , Skott P. , Smidt UM , Parving HH Long term effects of losinopril and atenolol on kidney function in hypertensive non insulin dependent diabetic subjects with diabetic nephropathy . Diabetes 1997;46:1182-8.

Fogari R. , Zoppi A. , Corradi L. et al. Long term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type 2 diabetes and impaired renal function . J Human Hypertension 1991;13:47-53.

10.

Lewis EJ , Hunsicker LG , Bain RP , Rohde RD The effect of angiotensin converting enzyme inhibition on diabetic nephropathy . N Eng J Med 1993;329:1456-62.

11.

Ravid M. , Savin H. , Jupin I. , Bental T. , Katz B. , Lishner M. Long term stabilizing effect of angiotensin converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type 2 diabetic patient . Ann Intern Med 1993;118:577-81.

12.

Rossing K. , Jacobsen P. , Pietraszek L. , Parving HH Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy. Diabetes Care 2003;26:2268-74.

13.

Mogensen CE , Neldam S. , Tikkanen I. et al. Randomized controlled trial of dual blockade of renin angiotensin system in patients with hypertension, macroalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria study (CALM). BMJ 2000; 312:1440-4.

14.

Rossing K. , Christensen PK , Jensen BR , Parving HH Dual blockade of the renin angiotensin system in diabetic nephropathy: a randomized double blind cross over study. Diabetes Care 2002;25:95-100.

15.

Jacobsen P. , Andersen S. , Rossing K. , Hansen BV , Parving HH Dual blockade of the renin angiotensin system in type 1 patients with diabetic nephropathy . Nephrol Dial Transplant 2002;17:1019-24.

16.

Ritz E. Albuminuria and vascular damage - the vicious twin. N Engl J Med 2003;348:2349-52.

17.

Gall MA , Houggard P. , Borch-Johnsen K. , Parving HH Risk factors for development of incipient and overt diabetic nephropathy in patients with non insulin dependent diabetes mellitus: a prospective, observational study. BMJ 1997;314:783-8.

18.

Adler AI , Stevens RJ , Manley SE , Bilous RW , Cull CA , Holman RR Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32.

19.

Tobe SW , McFarlane PA , Naimark DM Microalbuminuria in diabetes mellitus. Can Med Ass J 2002:167:499-503.

20.

Gerstein H. , Mann JFE , Yi Q. et al. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and non diabetic individuals. JAMA 2001;286:421-6.

21.

Eurich DT , Majumdar SR , Tsuyuki RT , Johnson JA Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 2004;27:1330-4.

22.

Parving HH , Mauer M. , Ritz E. Diabetic Nephropathy. In: Brenner BM, Eds Brenner and Rectors The Kidney. 7th Ed. vol 2. Philadelphia; Saunders 2004:1777-818.

23.

Keller CK , Bergis KH , Fliser D. , Ritz E. Renal findings patients with short term type 2 diabetes. J Am Soc Nephrol 1996;7:2627-35.

24.

Vanhoutte PM Endothelium and control of vascular function: state of the art lecture. Hypertension 1989 ;13:658-67.

25.

Hollenberg NK , Fisher NDL , Prise DA Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-92.

26.

Huang XR , Chen WY , Truong LD , Lan HY Chymase is upregulated in diabetic nephropathy; implications for an alternative pathway of angiotensin II - mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003;14:1738-47.

27.

van den Meiracker AH , Man in 't Veld AJ , Admiraal PJ et al. Partial escape of ACE inhibition during prolonged ACE inhibitor treatment; does it exist and does it effect the antihypertensive response? J Hypertens 1992;10: 803-12.

28.

Nussberger J. , Brunner DB , Wreber B. , Brunner HR Plasma angiotensins under sustained converting enzyme inhibition with enalapril in normal humans . J Hypertens 1985;3(suppl):S269-S270.

29.

Cao Z. , Bonnet F. , Candido R. et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 2002;13:1773-87.

30.

Cao Z. , Kelly DJ , Cox A. et al. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int 2000;58:2437-51.

31.

Wolf G. , Ziyadeh FN , Thaiss F. et al. Angiotensin II stimulates expression of the chemokine Rantes in rat glomerular endothelial cells: Role of angiotensin type 2 receptor. J Clin Invest 1997;100:1047-58.

32.

Chobanian AV , Barkis GL , Black HR et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72.

33.

2003 European Society of Hypertension - European society of cardiology guidelines for the management of arterial hypertension . J Hypertens 2003;21:1011-53.

34.

Brenner BM , Cooper ME , De Zeeuw et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy NEJM 2001;345:861-9.

35.

Jacobsen P. , Tarnow L. , Carstensen B. et al. Genetic variation in the renin angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol 2003;14:2843-50.

36.

Andersen S. , Tarnow L. , Cambien F. et al. Long term renoprotective effects of losartan in diabetic nephropathy; interaction with ACE insertion / deletion genotypes. Diabetes Care 2003;26:1501-06.

37.

Parving HH , Lehnert H. , Brocher-Mortensen J. et al. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.

38.

Rossing K. , Christensen PK , Hansen BV et al. Optimal dose of Candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double blind randomized cross over study. Diabetes Care 2003;26:150-5.

39.

Ferrari P. , Marti HP , Pfister M. , Frey FJ Additive antiproteinuric effect of Combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002;20:125-30.

40.

Kincaid Smith P. , Fiarley K. , Packham D. Randomized controlled cross over study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria . Nephrol Dial Transplant 2002;17:597-601.

41.

ADA Standards of medical care in diabetes. Diabetes Care 2004;27 (suppl):S15-S35.

42.

Bakris GL , Williams M. , Dwarkin L. et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000 ;36:646-61.

43.

Chobanian AV , Barkis GL , Black HR et al. Seventh report of the Joint National Committee on prevention, dectection, evaluation and treatment of high blood pressure. Hypertension 2003;42:1206-52.

44.

UK Prospective Diabetes Study Group. Tight control of blood pressure and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.

45.

Hansson L. , Zanchetti A. , Carruthers SG et al. Effects of intensive blood pressure lowering and low dose aspirin in principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351:1755-62.

46.

Ruilope LM , de la Sierra A. , Moreno E. et al. Prospective comparison of therapeutic attitudes in hypertensive type 2 diabetic participants uncontrolled on monotherapy. A randomized trial: the EDICTA Study. J Hypertens 1999;17:1917-23.

47.

Jacobsen P. , Andersen S. , Jensen BR , Parving HH Additive effect of ACE inhibition and angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy . J Am Soc Nephrol 2003;14:992-9.

48.

Agarwal R. Add on angiotensin receptor blockade with maximized ACE inhibition . Kidney Int 2001;59:2282-9.

49.

Andersen S. , Rossing P. , Juhl TR , Deinum J. , Parving HH Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 2002;17:1413-18.

50.

Gibbs CR , Beevers DG , Lip GY The management of hypertensive diseases in black patients. QJM 1999;92:187-92.

51.

Exner DV , Dries DL , Domanski MJ , Cohn JN Lesser response to angiotensin converting enzyme inhibitor therapy in black as compared with white patients in left ventricular dysfunction. N Eng J Med 2001; 344:1351-7.

52.

Agarwal R. , Siva S. , Dunn SR , Sharma K. Add on angiotensin II receptor blockade lowers urinary transforming growth factor beta levels. Am J Kidney Dis 2002;39:486-92.

53.

Cooper M. , Boner G. Dual blockade of the renin angiotensin system in diabetic nephropathy . Diabet Med 2004;21(suppl):15-18.

54.

Wade VL , Gleason BL Dual blockade of the renin angiotensin system in diabetic nephropathy . Ann Pharmacother 2004;38:1278-82.

55.

Parvanova A. , Pisoni R. , Dimitov BD et al. Relative renoprotective effect of ACE inhibitors (ACE I), Angiotensin II antagonists (ATA), ACE I and ATA combination and dihydropyridine calcium channel blockers (dCCB's) in overt diabetic nephropathy of type 2 diabetes (Abstract). J Am Soc Nephrol 2001;12:153A.

56.

Nakao N. , Yoshimura A. , Morita H. et al. Combination treatment of angiotensin II receptor blocker and angiotensin converting enzyme inhibitor in non diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003 ;361:117-24; erratum. Kidney Int 2003;361: 1230.

57.

58.

Jacobsen P. , Andersen S. , Rossing K. et al. Dual blockade of the renin angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy . Kidney Int 2003;63:1874-80.

59.

McMurray JJV , Ostergren J. , Swedberg K. et al. Effects of Candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting enzyme inhibitors: the CHARM Added Trial. Lancet 2003;363:767-71.